Novo Nordisk’s GLP-1 misses goal in closely watched Alzheimer’s trials
The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight loss and heart health, might also help combat neurodegeneration.
Guiding Obstetric Care and Treatment Decisions for Women With Prior GLP-1 Receptor Agonist Use
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as liraglutide and semaglutide, have revolutionized treatment of obesity. Obesity and obesity-related comorbidities increase the risks of adverse outcomes such as miscarriage, congenital malformations, preterm birth, gestational diabetes, and preeclampsia, which can have significant long-term consequences for mother and infant. By enabling women to begin pregnancy at a lower […]
Increasing Postpartum Use of GLP-1 Receptor Agonists
This study uses data from the Danish Medical Birth Register to examine postpartum use of glucagon-like peptide 1 receptor agonists.
Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation
This cohort study examines gestational weight gain and pregnancy outcomes after glucagon-like peptide-1 (GLP-1) receptor agonist discontinuation.
Telehealth companies push GLP-1s beyond approved use
Telehealth companies are promoting GLP-1 medications such as Ozempic and Wegovy for cosmetic weight loss in non-obese patients, despite FDA limitations on their approved use, according to a Nov. 24 report from Bloomberg. About 93% of GLP-1 ads from telehealth companies focused on thinness and downplayed risks, according to research from Boulder-based University of Colorado […]
Will NVO’s U.S. Price Cuts Boost Access & Revive Semaglutide Demand?
Last week, Novo Nordisk NVO announced that its popular semaglutide-based GLP-1 injections, Wegovy (for obesity) and Ozempic (for diabetes), will be offered at a limited-time price of $199 per month for new self-pay patients in the United States, through March 31, 2026. Wegovy’s label includes cardiovascular, HFpEF, liver, and osteoarthritis indications, while Ozempic remains the […]
Eli Lilly 1st pharma company to reach $1 trillion market cap
Indianapolis-based Eli Lilly is the first publicly traded U.S. healthcare company to reach market capitalization over $1 trillion, elevating the drugmaker to an exclusive list dominated by tech giants. Eli Lilly’s shares peaked Nov. 21, giving the pharmaceutical company market capitalization above $1 trillion before slightly dipping to $950 billion, according to The Wall Street […]
Readout of Phase 3 Semaglutide Trials Marks Critical Moment in Alzheimer’s Research and Suggests Potential for Combination Therapies
Data provides new insights into targeting the diverse pathobiology of Alzheimer’s disease, an approach spearheaded by the ADDF NEW YORK, Nov. 24, 2025 /PRNewswire/ — Today, Novo Nordisk released topline results from their phase 3 Evoke and Evoke+ trials of semaglutide, an oral GLP-1…
Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer’s Trials – The Wall Street Journal
Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer’s Trials The Wall Street JournalView Full Coverage on Google News
Women who give up weight-loss jabs for pregnancy can suffer harmful weight gain
When women taking weight loss jabs stop their use because of pregnancy, the rebound weight gain brings health risks for their babies. Women who paused the injections before or shortly after conceiving were more likely to gain excess weight in pregnancy, a study has found. This made them more likely to develop diabetes or high […]